Octapharma AG: Final data from the NuProtect study published on the immunogenicity of Nuwiq® in previously untreated patients with severe haemophilia A

Octapharma AG: Final data from the NuProtect study published on the immunogenicity of Nuwiq® in previously untreated patients with severe haemophilia A

LACHEN, Switzerland, Feb. 23, 2021 /PRNewswire/ -- Octapharma announced today that the final results from the NuProtect study on the immunogenicity of Nuwiq® in previously untreated patients (PUPs) with severe haemophilia A have been published in the leading medical journal Thrombosis and Haemostasis (Liesner RJ et al. "Simoctocog Alfa (Nuwiq&r...

Read more: Octapharma AG: Final data from the NuProtect study published on the immunogenicity of Nuwiq® in prev...

More Articles …

  1. Moët Hennessy Announces A Partnership with Shawn JAY-Z Carter via the acquisition of 50% of Champagne Armand de Brignac
  2. Atlas Renewable Energy ranks top clean energy developer for corporate PPAs in Latin America, and in top ten globally
  3. Why Famtech Will Become a Major Trend in the Coming Years
  4. Positive BNC210 7-Day Dosing Pharmacokinetic Study Exceeds Blood Exposure Projected for Phase 2b PTSD Trial
  5. Gan & Lee Announces New Partnership with International Diabetes Federation
  6. 'Cashback and Covid: Changing Money Habits of Consumers
  7. Bank of Asia Powered Up for Its New Chapter of Growth
  8. Axon Evidence Completes Australian Government's Cyber Security Assessment for Hosting Public Safety Data
  9. State of Victoria Country Fire Authority Selects Zetron's Command and Control System to Improve Statewide Integrated Emergency Communications
  10. TTC Named First Approved DIA Marketplace Web Accessibility Services Supplier